Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-thymocyte globulin + interleukin-2 + adalimumab + exenatide
- Development stage
- Unknown
- Lead developer
- University of Miami Miller School of Medicine
- Modality
- Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination immunotherapy regimen, known as the DIPIT protocol, being investigated for the treatment of new-onset type 1 diabetes (T1D). Developed by investigators Camillo Ricordi and Jay Skyler at the University of Miami, the regimen consists of four agents: anti-thymocyte globulin (ATG), low-dose interleukin-2 (IL-2), adalimumab, and exenatide. The strategy employs a "reset and protect" approach: ATG depletes autoreactive T cells, low-dose IL-2 expands regulatory T cells (Tregs) to restore immune tolerance, adalimumab (a TNF inhibitor) reduces systemic and local inflammation, and exenatide (a GLP-1 receptor agonist) supports pancreatic beta-cell function and survival. The primary objective of this multi-drug intervention is to preserve endogenous insulin production in patients recently diagnosed with T1D.
- Other names
- DIPIT combination therapyATG + IL-2 + adalimumab + exenatideRicordi-Skyler combination therapy
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-2R (Interleukin-2/interleukin-15 receptor complex)GLP1R (GLP-1R)
Beyond the preview
Go deeper on anti-thymocyte globulin + interleukin-2 + adalimumab + exenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-thymocyte globulin + interleukin-2 + adalimumab + exenatide.